Generated by AI
Edgewise Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for severe muscle and cardiac disorders. The company’s current portfolio centers on precision medicine programs designed to address rare neuromuscular diseases and inherited heart conditions, with a platform built around small-molecule approaches that target key muscle proteins and pathways. Its work spans muscular dystrophy and hypertrophic cardiomyopathy research, as well as other disorders where abnormal muscle function plays a central role. Edgewise Therapeutics Inc. operates as a clinical-stage developer of medicines aimed at improving how muscle diseases are treated in specialized medical settings, supporting both neuromuscular and cardiovascular care.
Website1715 38th Street
Boulder, CO, 80301
United States
The latest articles about EWTX.
Edgewise Therapeutics reported net income of US$1,166.15 million in Q3 2026 and held a favorable End-of-Phase 2 meeting with the FDA that enabled submission of the STRATUS-HCM Phase 3 protocol for EDG-7500 in hypertrophic cardiomyopathy. The planned STRATUS-HCM program uses an echo independent, investigator guided dose escalation design across both obstructive and nonobstructive hypertrophic cardiomyopathy within a single global master protocol, which reflects how Edgewise Therapeutics is...
Tipranks Press Release.
Summary of Jul 2's posts. Generated by AI.
Summary of Dec 24's posts. Generated by AI.
No summary yet.
Summary of Jun 1's posts. Generated by AI.
Investors talking about EWTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.